Grifols, S.A. (GRFS) Coverage Initiated at Citigroup Inc.

Stock analysts at Citigroup Inc. assumed coverage on shares of Grifols, S.A. (NASDAQ:GRFS) in a report issued on Tuesday. The firm set a “buy” rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued research reports about the stock. Bank of America Corporation reiterated a “buy” rating on shares of Grifols, in a research note on Tuesday, July 4th. Zacks Investment Research cut shares of Grifols, from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Finally, BidaskClub cut shares of Grifols, from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the stock. Grifols, currently has a consensus rating of “Hold” and an average target price of $24.00.

ILLEGAL ACTIVITY NOTICE: “Grifols, S.A. (GRFS) Coverage Initiated at Citigroup Inc.” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://sportsperspectives.com/2017/11/02/grifols-s-a-grfs-coverage-initiated-at-citigroup-inc.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its stake in shares of Grifols, by 49.3% in the first quarter. Geode Capital Management LLC now owns 103,591 shares of the biotechnology company’s stock valued at $1,954,000 after buying an additional 34,193 shares during the period. Renaissance Technologies LLC bought a new stake in shares of Grifols, in the first quarter valued at about $4,439,000. California Public Employees Retirement System lifted its stake in shares of Grifols, by 2.2% in the second quarter. California Public Employees Retirement System now owns 414,700 shares of the biotechnology company’s stock valued at $8,763,000 after buying an additional 9,000 shares during the period. FMR LLC lifted its stake in shares of Grifols, by 2.7% in the second quarter. FMR LLC now owns 6,523,773 shares of the biotechnology company’s stock valued at $137,847,000 after buying an additional 171,192 shares during the period. Finally, Ameriprise Financial Inc. lifted its stake in shares of Grifols, by 16.1% in the first quarter. Ameriprise Financial Inc. now owns 13,277 shares of the biotechnology company’s stock valued at $251,000 after buying an additional 1,839 shares during the period. Institutional investors and hedge funds own 21.93% of the company’s stock.

Grifols, Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Analyst Recommendations for Grifols, (NASDAQ:GRFS)

Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply